Serum VEGF levels are related to the presence of pulmonary arterial hypertension in systemic sclerosis

Papaioannou, Andriana Ι.; Zakynthinos, Epaminondas; Κostikas, Κonstantinos; Kiropoulos, Theodoros; Koutsokera, Angela; Ziogas, Athanassios; Κουτρούμπας, Αθανάσιος; Sakkas, Lazaros I.; Gourgoulianis, Konstantinos; Daniil, Zoe

doi:10.1186/1471-2466-9-18

Cited by 67 publications

(43 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…48 Serum levels of VEGF were significantly elevated in SSc patients and the concentrations were especially elevated in SSc patients with systemic organ involvement. 49 In other studies, serum levels of VEGF were elevated and correlated with shorter disease duration, 50 systolic pulmonary artery pressure, 51 skin sclerosis and the capillary density of nail fold. 52 On the other hand, there is a study that did not find any association between plasma VEGF levels and disease activity.…”

Section: Vegfmentioning

confidence: 81%

Biomarkers in systemic sclerosis: Their potential to predict clinical courses

Hasegawa

2016

The Journal of Dermatology

View full text Add to dashboard Cite

The concept of a biomarker was defined as "a characteristic marker that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention" by the National Institutes of Health Biomarkers Definitions Working group in 2001. Clinical features, disease progress, therapeutic response and prognosis are heterogeneous among patients with systemic sclerosis (SSc). Therefore, biomarkers that can predict these matters are required for the progress of clinical practice. At present, SSc-specific autoantibodies are the most useful biomarkers for diagnosis and predicting clinical features. Otherwise, biomarkers specific only for SSc have not been identified yet. The glycoprotein krebs von den Lungen-6, surfactant protein-D and CCL18 are promising serum biomarkers of SSc-related interstitial lung diseases. Serum/plasma levels of brain natriuretic peptide and serum N-terminal pro-brain natriuretic peptide have been used as biomarkers for SSc-related pulmonary arterial hypertension. Other potential serum/plasma biomarkers for fibrosis and vascular involvement of SSc are connective tissue growth factor, interleukin-6, CCL2, CXCL4, intercellular adhesion molecule (ICAM)-1, P-selectin, vascular endothelial growth factor, von Willebrand factor, endostatin, endoglin and endothelin-1. In our multicenter prospective studies of Japanese early SSc, serum ICAM-1 levels were predictive for subsequent respiratory dysfunction and serum levels of CXCL8 and Pselectin were predictive for subsequent physical disability. Further large, multicenter, prospective, longitudinal studies will be needed to identify and validate critical biomarkers of SSc.

show abstract

Section: Vegfmentioning

confidence: 81%

Biomarkers in systemic sclerosis: Their potential to predict clinical courses

Hasegawa

2016

The Journal of Dermatology

View full text Add to dashboard Cite

show abstract

“…In the present study, VEGF was quantified in plasma and not in serum, in order to rule out any potential influence of platelet VEGF granule content release. Indeed, it has been reported that VEGF of platelet origin can interfere with the pathophysiology of pulmonary hypertension [41] and with VEGF quantification in serum [42]. The source of the endothelial cells involved in the vascular remodelling associated with pulmonary hypertension is unclear.…”

Section: Significant P-values Are Shown In Boldmentioning

confidence: 99%

Distinct patterns of circulating endothelial cells in pulmonary hypertension

Smadja¹,

Mauge²,

Sanchez³

et al. 2010

European Respiratory Journal

View full text Add to dashboard Cite

The respective abundance of circulating endothelial cells and endothelial progenitor cells may reflect the balance between vascular injury and repair. As pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) can share features of pulmonary remodelling, we postulated that the two disorders might be associated with different types of pulmonary endothelial dysfunction.We studied 25 consecutive patients undergoing cardiac catheterisation for suspected pulmonary hypertension. Nine patients had PAH, nine had CTEPH, and seven had normal pulmonary arterial pressure and served as controls. Circulating endothelial cells were isolated with CD146-coated beads. CD34+CD133+ cell and endothelial progenitor cell numbers were respectively determined by flow cytometry and cell culture, in peripheral vein and pulmonary artery blood. Plasma levels of soluble vascular endothelial growth factor (VEGF), soluble Eselectin and soluble vascular cell adhesion molecule (sVCAM) were measured by ELISA.No difference in progenitor counts or VEGF levels was found across the three groups. Compared to controls, circulating endothelial cell numbers were significantly increased in PAH but not in CTEPH, in keeping with the elevated soluble E-selectin and sVCAM levels found in PAH alone.In conclusion, PAH, in contrast to CTEPH, is associated with markers of vascular injury (circulating endothelial cells, soluble E-selectin and sVCAM) but not with markers of remodelling (endothelial progenitor cells, CD34+CD133+ cells and VEGF).

show abstract

“…Given the potent proangiogenic effects of VEGF, the role of this growth factor in the pathogenesis of SSc associated fibroproliferative alterations such as pulmonary artery hypertension (PAH) has been the subject of intense investigation. An evaluation of the relationships between pulmonary artery pressure, clinical and functional manifestations of SSc and serum VEGF levels showed that serum VEGF levels were increased in SSc patients with PAH and suggested a possible role of VEGF in the pathogenesis of PAH in SSc [141].…”

Section: Vascular Endothelial Growth Factor (Vegf)mentioning

confidence: 99%